BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9258763)

  • 1. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
    Weinstein RS
    J Bone Miner Res; 1997 Aug; 12(8):1314-5. PubMed ID: 9258763
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Chapurlat RD; Delmas PD; Liens D; Meunier PJ
    J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
    Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapy in fibrous dysplasia.
    Lane JM; Khan SN; O'Connor WJ; Nydick M; Hommen JP; Schneider R; Tomin E; Brand J; Curtin J
    Clin Orthop Relat Res; 2001 Jan; (382):6-12. PubMed ID: 11154006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
    Parisi MS; Oliveri B; Mautalen CA
    Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
    Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
    Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
    Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
    Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Liens D; Delmas PD; Meunier PJ
    Lancet; 1994 Apr; 343(8903):953-4. PubMed ID: 7909013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nonsurgical treatment of fibrous dysplasia.
    Chapurlat R; Meunier PJ
    Rev Rhum Engl Ed; 1999 Jan; 66(1):1-3. PubMed ID: 10036690
    [No Abstract]   [Full Text] [Related]  

  • 11. Further study of the therapy for fibrous dysplasia is necessary.
    Czerwiec FS; Collins M; Feuillan P; Shenker A
    J Bone Miner Res; 1997 Dec; 12(12):2128-30. PubMed ID: 9421248
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
    Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury.
    Nance PW; Schryvers O; Leslie W; Ludwig S; Krahn J; Uebelhart D
    Arch Phys Med Rehabil; 1999 Mar; 80(3):243-51. PubMed ID: 10084430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of monostotic fibrous dysplasia with pamidronate.
    Kos M; Luczak K; Godzinski J; Klempous J
    J Craniomaxillofac Surg; 2004 Feb; 32(1):10-5. PubMed ID: 14729043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
    Lee YS; Low SL; Lim LA; Loke KY
    Eur J Pediatr; 2001 Nov; 160(11):641-4. PubMed ID: 11760017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain.
    Fan TM; de Lorimier LP; O'Dell-Anderson K; Lacoste HI; Charney SC
    J Vet Intern Med; 2007; 21(3):431-9. PubMed ID: 17552447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
    Wilkinson JM; Jackson B; Eastell R
    Calcif Tissue Int; 2003 Oct; 73(4):326-31. PubMed ID: 12874697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical therapy in adults with fibrous dysplasia of bone.
    Chapurlat RD
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P114-9. PubMed ID: 17228999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.